LATEST NEWS

Bio Integrates 2021 – Engage with the community transforming the biotech sector

Click here for Track 1,  Click here for Track 2,  Click here for Track 3

MedTech Integrates 2021
All sessions now available on-demand!

Click here for Track 1,  Click here for Track 2,  Click here for Track 3

Pharma Integrates 2020 – Connect with pharma leaders pioneering change

Click here for Track 1,  Click here for Track 2,  Click here for Track 3, Click here for Track 4

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.

read more

MOST POPULAR READS

Lack of collaboration the biggest challenge in adopting blockchain, says IBM

READ MORE | 3 Minute Read

Backend, Baffling and Buzzing: Blockchain

READ MORE | 20 Minute Read

Technology

READ MORE | 7 Minute Read

The future of the pharmaceutical industry

READ MORE | 12 Minute Read

LIFE SCIENCE INTEGRATES INDUSTRY INSIGHTS

Treatment

READ MORE | 5 Minute Read

Technology

READ MORE | 7 minute read

Talent

READ MORE | 5 Minute Read

Tactics

READ MORE | 5 Minute Read

Considering The Patient

READ MORE | 5 Minute Read

Catapults

READ MORE | 5 Minute Read

MARCO MOHWINCKEL INSIGHTS

Marco Mohwinckel: Revolutionising Drug Discover With Big Data And AI

READ MORE | 10 Minute Read

Marco Mohwinckel:
Backend and Buzzing:
Blockchain

READ MORE | 20 Minute Read

Marco Mohwinckel:
The Disruptive Power
of Pharma AI

READ MORE | 10 Minute Read

VISIT OUR INSIGHTS AREAS

WHITE PAPERS

LATEST NEWS

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.

INDUSTRY INSIGHTS

Treatment

A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases. 

Technology

With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.

Talent

A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?

Tactics

In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.

ON TWITTER

WHITE PAPERS

LATEST NEWS

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.

INDUSTRY INSIGHTS

Treatment

A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases. 

Technology

With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.

Talent

A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?

Tactics

In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.

ON TWITTER

PREVIOUS EVENTS

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.